Search Result

Results for "

JAK2+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (16) Autophagy (3) Bacterial (1) Bcl-2 Family (1) Caspase (1) Drug Intermediate (1) FGFR (1) FLT3 (5) Interleukin Related (1) Isotope-Labeled Compounds (2) JAK (57) Ligands for Target Protein for PROTAC (1) Reference Standards (7) RET (2) STAT (7) VEGFR (1)
By Research Areas:	Cancer (44) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (13)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15315

Baricitinib Maximum Cited Publications 75 Publications Verification LY3009104; INCB028050	JAK	Inflammation/Immunology
Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and *JAK2* inhibitor with IC₅₀s of 5.9 nM and 5.7 nM, respectively.

HY-10409

Fedratinib 50+ Cited Publications TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2].

HY-18960

CHZ868 5+ Cited Publications	JAK	Cancer
CHZ868 is a type II *JAK2* inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

HY-13034

Gandotinib 4 Publications Verification LY2784544	JAK FLT3 FGFR VEGFR	Cancer
Gandotinib (LY2784544) is a potent *JAK2* inhibitor with IC₅₀ of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC₅₀ of 4, 25, 32, 44, and 95 nM.

HY-15315A

Baricitinib phosphate Maximum Cited Publications 75 Publications Verification LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2** inhibitor* with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-15270

BMS-911543 4 Publications Verification	JAK	Cancer
BMS-911543 is a selective *JAK2* inhibitor, with IC₅₀s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC₅₀, 75, 360, 66 nM, respectively).

HY-10410

TG101209 5 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-10409A

Fedratinib hydrochloride hydrate 50+ Cited Publications TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2].

HY-124727

ZT55	JAK Apoptosis	Cancer
ZT55 is an orally active and highly-selective *JAK2* inhibitor with an IC₅₀ value of 0.031 μM. ZT55 inhibits the proliferation of JAK2 ^V617F-expressing HEL cell lines and induces apoptosis and cycle arrest. ZT-55 also effectively inhibits the growth of HEL xenograft tumours in a mice model. ZT-55 can be used in studies of myeloproliferative neoplasms, polycythemia vera and primary thrombocythemia .

HY-50856S

Deuruxolitinib CTP-543; Ruxolitinib d₈; Deuterated Ruxolitinib	JAK	Inflammation/Immunology
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and *JAK2* inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective *JAK2* inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-13775

XL019 5 Publications Verification	JAK Apoptosis	Cancer
XL019?is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 ^[2].

HY-15480

NSC 42834 3 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2*, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-15315S

Baricitinib-d5 LY3009104-d₅; INCB028050-d₅	JAK	Inflammation/Immunology
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-19631A

Ilginatinib 1 Publications Verification NS-018	JAK	Cancer
Ilginatinib (NS-018) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-14722A

NVP-BSK805 dihydrochloride 3 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722

NVP-BSK805 3 Publications Verification	JAK	Cancer
NVP-BSK805 is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-19631B

Ilginatinib hydrochloride 1 Publications Verification NS-018 hydrochloride	JAK	Cancer
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631

Ilginatinib maleate 1 Publications Verification NS-018 maleate	JAK	Cancer
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-115452

G5-7	JAK Apoptosis	Cancer
G5-7, an orally active and allosteric *JAK2* inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr ¹⁰⁶⁸) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study .

HY-W062703S

(Rac)-Ruxolitinib-d9 (Rac)-INCB18424-d₉; Ruxotinib racemate-d₉	Isotope-Labeled Compounds JAK	Cancer
(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .

HY-137756

JAK2-IN-6 1 Publications Verification	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .

HY-175684

JAK2-IN-14	JAK STAT Apoptosis	Cancer
JAK2-IN-14 is an orally active *JAK2* inhibitor with an IC₅₀ of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and *TYK2, respectively. JAK2-IN-14* inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) .

HY-15315R

Baricitinib (Standard) LY3009104 (Standard); INCB028050 (Standard)	Reference Standards JAK	Inflammation/Immunology
Baricitinib (Standard) is the analytical standard of Baricitinib. This product is intended for research and analytical applications. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and *JAK2* inhibitor with IC₅₀s of 5.9 nM and 5.7 nM, respectively.

HY-167846

YLIU-4-105-1	JAK	Cancer
YLIU-4-105-1 is a Type II JAK2 inhibitor. YLIU-4-105-1 binds to the ATP-binding pocket of JH1. YLIU-4-105-1 has in vivo pharmacodynamic activity as evidenced by inhibiting pSTAT5, reducing spleen to body weight, and lowering blood reticulocyte counts in a dose-dependent manner .

HY-162248

JAK1/2-IN-1	JAK Interleukin Related	Inflammation/Immunology Cancer
JAK1/2-IN-1 is a potent JAK1 and *JAK2* inhibitor with IC₅₀ values of 0.4 nM and 8.1 nM, respectively. JAK1/2-IN-1 also inhibits IL-4 and IL-13 with IC₅₀s of 136.5 nM and 19.1 nM, respectively (WO2023244775A1; Example 33a) .

HY-16020

AC-430 hydrobromide	JAK	Cancer
AC-430 hydrobromide (example 1) is a potent *JAK2* inhibitor. AC-430 hydrobromide can be used for the research of myeloproliferative disorders and cancer .

HY-18301

JAK-IN-35	JAK	Cancer
JAK-IN-35 (compound XLVII) is a *JAK2* inhibitor that canb be used in cancer research .

HY-117810

JAK2-IN-1	JAK	Inflammation/Immunology
JAK2-IN-1 (eExample 2) is a *JAK2* inhibitor, and can be used for research of proliferative disease, inflammatory disease, or renal disease .

HY-129679

NMS-P953	JAK	Cancer
NMS-P953 (compound 28) is an orally active *JAK2* inhibitor (IC₅₀=0.008 μM) with antitumor activity .

HY-177131

Soficitinib	JAK	Inflammation/Immunology
Soficitinib (Compound 20) is a selective tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) inhibitor, with IC₅₀ values of 0.5 nM and 1.2 nM, respectively. Soficitinib shows promise for research into autoimmune diseases (such as psoriasis, rheumatoid arthritis) and inflammatory diseases .

HY-172957

JNN-5	JAK	Cancer
JNN-5 is a potent and selective *JAK2* inhibitor with an IC₅₀ of 0.41 nM. JNN-5 shows strong antiproliferative activities in the TNBC cell lines (MDA-MB-468, MDA-MB-213, HCC70, MDA-MB-157) .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-10409R

Fedratinib (Standard) TG-101348 (Standard); SAR 302503 (Standard)	Reference Standards JAK Apoptosis	Cancer
Fedratinib (Standard) is the analytical standard of Fedratinib. This product is intended for research and analytical applications. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2].

HY-16021

AC-430	JAK	Inflammation/Immunology
AC-430 is a *JAK2* inhibitor. AC-430 can be used in the research of rheumatoid arthritis .

HY-15315S1

Baricitinib-d3 LY3009104-d₃; INCB028050-d₃	JAK	Inflammation/Immunology
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315AR

Baricitinib phosphate (Standard) LY3009104 phosphate (Standard); INCB028050 phosphate (Standard)	JAK Reference Standards	Inflammation/Immunology
Baricitinib (phosphate) (Standard) is the analytical standard of Baricitinib (phosphate). This product is intended for research and analytical applications. Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively.

HY-W064657

Momelotinib dihydrochloride	JAK	Others
Momelotinib (dihydrochloride) is a *JAK1/JAK2* inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis .

HY-Y1049

2-Amino-6-bromopyridine	Bacterial Drug Intermediate	Infection
2-Amino-6-bromopyridine is an intermediate. 2-Amino-6-bromopyridine is also a PqsR ligand with a K_d value of 6.8 μM in SPR assay. 2-Amino-6-bromopyridine shows weak antagonistic activity. 2-Amino-6-bromopyridine can be used in the synthesis of JAK2 inhibitors, MSK1 inhibitors, and in the research of Pseudomonas aeruginosa infection ^[2] .

HY-174988

JAK2-IN-13	JAK STAT	Cancer
JAK2-IN-13 is a potent and orally active *JAK2* inhibitor with an IC₅₀ of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .

HY-120604

BVB808 NVP_BVB808	JAK STAT	Cancer
BVB808 (NVP_BVB808) is a selective *JAK2* inhibitor with approximately 10-fold selectivity for *JAK2* over other JAK family members (such as JAK1, JAK3 or TYK2) in vitro. BVB808 inhibits the activity of *JAK2* and reduces the phosphorylation of STAT5, thereby blocking the *JAK2*-dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research .

HY-178936

JAK2-IN-15	JAK STAT	Inflammation/Immunology Cancer
JAK2-IN-15 is an orally active, potent, selective *JAK2* inhibitor (IC₅₀ = 1.17 nM). JAK2-IN-15 can inhibit the *AK2-STAT* signaling pathway. JAK2-IN-15 significantly improves key pathological indicators such as hematocrit and splenomegaly in an Epoetin beta (HY-114134) (rhEPO)-induced mouse model. JAK2-IN-15 can be used for the study of Polycythemia Vera (PV) .

HY-18293

NSC 33994	JAK Autophagy	Cancer
NSC 33994 (G6) is a selective *JAK2* inhibitor, with an IC₅₀ of 60 nM .

HY-10193A

(1R)-AZD-1480	JAK	Cancer
(1R)-AZD-1480 is the (1R) chiral isomer of AZD-1480, an ATP competitive JAK1 and *JAK2* inhibitor .

HY-176479

JAK2-IN-12	JAK	Cancer
JAK2-IN-12 (compound 23) is a *JAK2* inhibitor with a pIC₅₀ of 8.2. JAK2-IN-12 can be used for study of myelofibrosi .

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-19631AR

Ilginatinib (Standard) NS-018 (Standard)	JAK Reference Standards	Cancer
Ilginatinib (Standard) is the analytical standard of Ilginatinib. This product is intended for research and analytical applications. Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).

HY-161967

JAK2/FLT3-IN-3	FLT3 JAK Apoptosis	Cancer
JAK2/FLT3-IN-3 (11r) is a dual FLT3 and *JAK2* inhibitor, with IC₅₀ values of 2.01 nM, 0.51 nM and 104.40 nM for JAK2, FLT3 and JAK3, respectively. JAK2/FLT3-IN-3 (11r) induces apoptosis and possesses antitumor activity .

HY-10409AR

Fedratinib hydrochloride hydrate (Standard) TG-101348 hydrochloride hydrate (Standard); SAR 302503 hydrochloride hydrate (Standard)	Reference Standards JAK Apoptosis	Cancer
Fedratinib (hydrochloride hydrate) (Standard) is the analytical standard of Fedratinib (hydrochloride hydrate). This product is intended for research and analytical applications. Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2].

HY-10409S

Fedratinib-d9 TG-101348-d₉; SAR 302503-d₉	Isotope-Labeled Compounds Apoptosis JAK	Cancer
Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2] .

Cat. No.	Product Name	Chemical Structure

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and *JAK2* inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata .

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-W062703S

(Rac)-Ruxolitinib-d9
(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: